South Korea · Delayed Price · Currency is KRW KBIO LABS Statistics
Total Valuation
KBIO LABS has a market cap or net worth of KRW 21.46 billion. The enterprise value is 8.19 billion.
| Market Cap | 21.46B |
| Enterprise Value | 8.19B |
Important Dates
The next estimated earnings date is Friday, August 14, 2026.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
KBIO LABS has 23.10 million shares outstanding. The number of shares has decreased by -43.26% in one year.
| Current Share Class | 23.10M |
| Shares Outstanding | 23.10M |
| Shares Change (YoY) | -43.26% |
| Shares Change (QoQ) | +446.13% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 15.44M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.26 |
| PB Ratio | 0.21 |
| P/TBV Ratio | 0.41 |
| P/FCF Ratio | 2.71 |
| P/OCF Ratio | 2.70 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.50, with an EV/FCF ratio of 1.04.
| EV / Earnings | n/a |
| EV / Sales | 0.10 |
| EV / EBITDA | 14.50 |
| EV / EBIT | n/a |
| EV / FCF | 1.04 |
Financial Position
The company has a current ratio of 5.84, with a Debt / Equity ratio of 0.01.
| Current Ratio | 5.84 |
| Quick Ratio | 5.02 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 1.44 |
| Debt / FCF | 0.10 |
| Interest Coverage | -7.66 |
Financial Efficiency
Return on equity (ROE) is -2.63% and return on invested capital (ROIC) is -0.97%.
| Return on Equity (ROE) | -2.63% |
| Return on Assets (ROA) | -0.20% |
| Return on Invested Capital (ROIC) | -0.97% |
| Return on Capital Employed (ROCE) | -0.36% |
| Weighted Average Cost of Capital (WACC) | 8.05% |
| Revenue Per Employee | 2.17B |
| Profits Per Employee | -61.58M |
| Employee Count | 38 |
| Asset Turnover | 0.69 |
| Inventory Turnover | 12.07 |
Taxes
In the past 12 months, KBIO LABS has paid 162.07 million in taxes.
| Income Tax | 162.07M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -31.33% in the last 52 weeks. The beta is 0.71, so KBIO LABS's price volatility has been lower than the market average.
| Beta (5Y) | 0.71 |
| 52-Week Price Change | -31.33% |
| 50-Day Moving Average | 1,409.24 |
| 200-Day Moving Average | 1,373.54 |
| Relative Strength Index (RSI) | 30.38 |
| Average Volume (20 Days) | 150,357 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, KBIO LABS had revenue of KRW 82.64 billion and -2.34 billion in losses. Loss per share was -100.19.
| Revenue | 82.64B |
| Gross Profit | 11.38B |
| Operating Income | -379.93M |
| Pretax Income | -2.62B |
| Net Income | -2.34B |
| EBITDA | 564.57M |
| EBIT | -379.93M |
| Loss Per Share | -100.19 |
Balance Sheet
The company has 64.74 billion in cash and 814.40 million in debt, with a net cash position of 63.92 billion or 2,767.36 per share.
| Cash & Cash Equivalents | 64.74B |
| Total Debt | 814.40M |
| Net Cash | 63.92B |
| Net Cash Per Share | 2,767.36 |
| Equity (Book Value) | 104.47B |
| Book Value Per Share | 465.93 |
| Working Capital | 69.01B |
Cash Flow
In the last 12 months, operating cash flow was 7.94 billion and capital expenditures -28.22 million, giving a free cash flow of 7.91 billion.
| Operating Cash Flow | 7.94B |
| Capital Expenditures | -28.22M |
| Depreciation & Amortization | 944.50M |
| Net Borrowing | -786.21M |
| Free Cash Flow | 7.91B |
| FCF Per Share | 342.43 |
Margins
Gross margin is 13.77%, with operating and profit margins of -0.46% and -2.83%.
| Gross Margin | 13.77% |
| Operating Margin | -0.46% |
| Pretax Margin | -3.17% |
| Profit Margin | -2.83% |
| EBITDA Margin | 0.68% |
| EBIT Margin | -0.46% |
| FCF Margin | 9.57% |
Dividends & Yields
KBIO LABS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 43.26% |
| Shareholder Yield | 43.26% |
| Earnings Yield | -10.90% |
| FCF Yield | 36.86% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 14, 2026. It was a reverse split with a ratio of 0.2.
| Last Split Date | Apr 14, 2026 |
| Split Type | Reverse |
| Split Ratio | 0.2 |
Scores
KBIO LABS has an Altman Z-Score of 2.09 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.09 |
| Piotroski F-Score | 3 |